Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies

Arthritis Research & Therapy

Fabrizio Conti¹  Cristiano Alessandri¹  Daniela Bompane¹  Michele Bombardieri¹  Francesca Romana Spinelli¹  Anna Carlotta Rusconi²  Guido Valesini¹ 

[1] Cattedra di Reumatologia, Dipartimento di Clinica e Terapia Medica Applicata – Università degli Studi di Roma 'La Sapienza', Rome, Italy

[2] Dipartimento di Scienze Psichiatriche e Medicina Psicologica, Università degli Studi di Roma 'La Sapienza', Rome, Italy

关键词: systemic lupus erythematosus;    psychiatric disorders;    mood disorders;    autoantibodies;    anti-endothelial-cell antibodies;   

Others  :  1101241
DOI  :  10.1186/ar1198

 received in 2004-03-29, accepted in 2004-05-18,  发布年份 2004

【 摘 要 】

This study was performed to determine the correlation between psychiatric manifestations and several autoantibodies that might participate in the pathogenesis of psychiatric disorders in the course of systemic lupus erythematosus (SLE). Fifty-one unselected outpatients with SLE were enrolled. Psychiatric evaluation was performed according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition. The prevalence of antibodies against endothelial cells (AECA), cardiolipin, β2 glycoprotein I, Ro, Ro52, La, glial fibrillary acidic protein, ribosomal P protein, dsDNA, and nucleosomes was assessed by experimental and commercial enzyme-linked immunosorbent assays. According to the cutoff value, AECA were present in 11 of 17 (64.7%) SLE patients with psychosis and mood disorders and in 10 of 34 (29.4%) patients without psychiatric manifestations other than anxiety (P = 0.03). Moreover, the AECA binding index was significantly higher in the first group (P = 0.03). Conversely, no significant correlation was found between the presence of the other autoantibodies studied and psychiatric involvement. The results of this study suggest a relationship between AECA and psychosis and mood disorders in SLE, supporting the hypothesis of a biological origin of these disturbances.

【 授权许可】

   
2004 Conti et al.; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]ACR ad hoc committee on Neuropsychiatric Lupus Nomenclature: The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999, 42:599-608.
• [2]Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsanoja R, Auvinen A: Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 2001, 45:419-423.
• [3]Buchbinder R, Hall S, Littlejohn GO, Ryan PF: Neuropsychiatric manifestations of systemic lupus erythematosus. Aust N Z J Med 1988, 18:679-684.
• [4]Johnson RT, Richardson EP: The neurological manifestations of systemic lupus erythematosus. Medicine 1968, 47:337-369.
• [5]Wekking EM: Psychiatric symptoms in systemic lupus erythematosus: an update. Psychosom Med 1993, 55:219-228.
• [6]Iverson GL, McCracken LM: Attributing psychopathology to systemic lupus erythematosus: some methodological considerations. Ann Rheum Dis 1992, 51:134-135.
• [7]Lewis DA, Smith RE: Steroid induced psychiatric syndromes: a report of 14 cases and review of literature. J Affect Disord 1983, 5:319-332.
• [8]Hay EM, Black D, Huddy A, Creed F, Tomenson B, Bernstein RM, Holt PJ: Psychiatric disorder and cognitive impairment in systemic lupus erythematosus. Arthritis Rheum 1992, 35:411-416.
• [9]Lindal E, Thorlacius S, Steinsson K, Stefansson JG: Psychiatric disorders among subjects with systemic lupus erythematosus in an unselected population. Scand J Rheumatol 1995, 24:346-351.
• [10]Segui J, Ramos-Casals M, Garcia-Carrasco M, de Flores T, Cervera R, Valdes M, Font J, Ingelmo M: Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: a longitudinal study of active and inactive stages of the disease. Lupus 2000, 9:584-588.
• [11]Shortall E, Isenberg D, Newman SP: Factors associated with mood and mood disorders in SLE. Lupus 1995, 4:272-279.
• [12]Greenwood DL, Gitlits VM, Alderuccio F, Sentry JW, Toh BH: Autoantibodies in neuropsychiatric lupus. Autoimmunity 2002, 35:79-86.
• [13]Bonfa E, Elkon KB: Clinical and serologic associations of the antiribosomal P protein antibody. Arthritis Rheum 1986, 29:981-985.
• [14]Teh LS, Isenberg DA: Antiribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal. Arthritis Rheum 1994, 37:307-315.
• [15]Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, Elkon KB: Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987, 317:265-271.
• [16]Isshi K, Hirohata S: Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1996, 39:1483-1490.
• [17]Schneebaum AB, Singleton JD, West SG, Blodgett JK, Allen LG, Cheronis JC, Kotzin BL: Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991, 90:54-62.
• [18]Teh LS, Bedwell AE, Isenberg DA, Gordon C, Emery P, Charles PJ, Harper M, Amos N, Williams BD: Antibodies to protein P in systemic lupus erythematosus. Ann Rheum Dis 1992, 51:489-494.
• [19]Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
• [20]American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association; 1994.
• [21]First MB, Spitzer RL, Gibbon M, Williams JB: Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I/P), Computer Program Handbook. Version 2.0. New York: New York State Psychiatric Institute, Biometrics Research Department; 1996.
• [22]Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35:630-640.
• [23]Vismara A, Meroni PL, Tincani A, Harris EN, Barcellini W, Brucato A, Khamashta M, Hughes GR, Zanussi C, Balestrieri G: Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol 1988, 74:247-253.
• [24]van der Zee JM, Siegert CE, de Vreede TA, Daha MR, Breedveld FC: Characterization of anti-endothelial cell antibodies in systemic lupus erythematosus (SLE). Clin Exp Immunol 1991, 84:238-244.
• [25]Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590.
• [26]Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, Valdez CR, Escalante A, del Rincon I, Gronseth G, Rhine CB, Padilla P, McGlasson D: Neuropsychiatric syndromes in lupus: prevalence using standardized definition. Neurology 2002, 58:1214-1220.
• [27]Mok CC, Lau CS, Wong RWS: Neuropsychiatric manifestations and their clinical associations in Southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2001, 28:766-771.
• [28]Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A: The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001, 57:496-500.
• [29]D'Cruz DP, Houssiau FA, Ramirez G, Baguley E, McCutcheon J, Vianna J, Haga HJ, Swana GT, Khamashta MA, Taylor JC: Antibodies to endothelial cells in systemic lupus erythematosus: a potential marker for nephritis and vasculitis. Clin Exp Immunol 1991, 85:254-261.
• [30]Carvalho D, Savage CO, Black CM, Pearson JD: IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 1996, 97:111-119.
• [31]Bordron A, Dueymes M, Levy Y, Jamin C, Leroy JP, Piette JC, Shoenfeld Y, Youinou PY: The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 1998, 101:2029-2035.
• [32]Del Papa N, Guidali L, Spatola L, Bonara P, Borghi MO, Tincani A, Balestrieri G, Meroni PL: Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol 1995, 13:179-185.
• [33]Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K, Koike T, Balestrieri G, Tincani A, Hughes GR, Meroni PL: Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997, 40:551-561.
• [34]Papa ND, Raschi E, Moroni G, Panzeri P, Borghi MO, Ponticelli C, Tincani A, Balestrieri G, Meroni PL: Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro. Lupus 1999, 8:423-429.
• [35]Wellicome SM, Kapahi P, Mason JC, Lebranchu Y, Yarwood H, Haskard DO: Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1993, 92:412-418.
• [36]Belmont HM, Buyon J, Giorno R, Abramson S: Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum 1994, 37:376-383.
• [37]Carson CW, Beall LD, Hunder GG, Johnson CM, Newman W: Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol 1993, 20:809-814.
• [38]Song J, Park YB, Lee WK, Lee KH, Lee SK: Clinical associations of anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Rheumatol Int 2000, 20:1-7.
• [39]Meroni PL, Tincani A, Sepp N, Raschi E, Testoni C, Corsini E, Cavazzana I, Pellegrini S, Salmaggi A: Endothelium and the brain in CNS lupus. Lupus 2003, 12:919-928.
• [40]Harris EN, Gharavi AE, Asherson RA, Boey ML, Hughes GR: Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol 1984, 2:47-51.
• [41]Asherson RA, Khamashta MA, Gil A, Vazquez JJ, Chan O, Baguley E, Hughes GR: Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med 1989, 86:391-399.
• [42]Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GR: Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994, 37:568-571.
• [43]Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, Hughes GR: Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003, 30:985-992.
• [44]Caronti B, Calderaro C, Alessandri C, Conti F, Tinghino R, Pini C, Palladini G, Valesini G: Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmun 1998, 11:425-429.
• [45]Caronti B, Calderaro C, Alessandri C, Conti F, Tinghino R, Palladini G, Valesini G: Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage. Clin Exp Immunol 1999, 115:214-219.
• [46]Chan TM, Yu PM, Tsang KL, Cheng IK: Endothelial cell binding by human polyclonal anti-DNA antibodies: relationship to disease activity and endothelial functional alterations. Clin Exp Immunol 1995, 100:506-513.
• [47]Chan TM, Cheng IK: Identification of endothelial cell membrane proteins that bind anti-DNA antibodies from patients with systemic lupus erythematosus by direct or indirect mechanisms. J Autoimmun 1997, 10:433-439.
• [48]Moscato S, Pratesi F, Bongiorni F, Scavuzzo MC, Chimenti D, Bombardieri S, Migliorini P: Endothelial cell binding by systemic lupus antibodies: functional properties and relationship with anti-DNA activity. J Autoimmun 2002, 18:231-238.
• [49]Arnett FC, Reveille JD, Moutsopoulos HM, Georgescu L, Elkon KB: Ribosomal P autoantibodies in SLE. Arthritis Rheum 1996, 39:1833-1839.
• [50]Gerli R, Caponi L, Tincani A, Scorza R, Sabbadini MG, Danieli MG, De Angelis V, Cesarotti M, Piccirilli M, Quartesan R, Moretti P, Cantoni C, Franceschini F, Cavazzana I, Origgi L, Vanoli M, Bozzolo E, Ferrario L, Padovani A, Gambini O, Vanzulli L, Croce D, Bombardieri S: Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology 2002, 41:1357-1366.
• [51]Yoshio T, Masuyama J, Ikeda M, Tamai K, Hachiya T, Emori T, Mimori A, Takeda A, Minota S, Kano S: Quantification of antiribosomal P0 protein antibodies by ELISA with recombinant P0 fusion protein and their association with central nervous system disease in systemic lupus erythematosus. J Rheumatol 1995, 22:1681-1687.
• [52]Frampton G, Moriya S, Pearson JD, Isenberg DA, Ward FJ, Smith TA, Panayiotou A, Staines NA, Murphy JJ: Identification of candidate endothelial cell autoantigens in systemic lupus erythematosus using a molecular cloning strategy: a role for ribosomal P protein P0 as an endothelial cell autoantigen. Rheumatology 2000, 39:1114-1120.
• [53]Sanna G, Piga M, Terryberry JW, Peltz MT, Giagheddu S, Satta L, Ahmed A, Cauli A, Montaldo C, Passiu G, Peter JB, Shoenfeld Y, Mathieu A: Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus 2000, 9:573-583.
• [54]Kato S, Gondo T, Hoshii Y, Takahashi M, Yamada M, Ishihara T: Confocal observation of senile plaques in Alzheimer's disease: senile plaque morphology and relationship between senile plaques and astrocytes. Pathol Int 1998, 48:332-340.
• [55]Tanaka J, Nakamura K, Takeda M, Tada K, Suzuki H, Morita H, Okado T, Hariguchi S, Nishimura T: Enzyme-linked immunosorbent assay for human autoantibody to glial fibrillary acidic protein: higher titer of the antibody is detected in serum of patients with Alzheimer's disease. Acta Neurol Scand 1989, 80:554-560.
• [56]Newcombe J, Gahan S, Cuzner ML: Serum antibodies against central nervous system proteins in human demyelinating disease. Clin Exp Immunol 1985, 59:383-390.
• [57]Trysberg E, Nylen K, Rosengren LE, Tarkowski A: Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003, 48:2881-2887.
• [58]Utset TO, Golden M, Siberry G, Kiri N, Crum RM, Petri M: Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system lupus and Sjogren's syndrome. J Rheumatol 1994, 21:2039-2045.